- €6.19bn
- €17.49bn
- €7.52bn
Brief: Moody's Ratings Upgrades Grifols' Rating To B2, Outlook Remains Positive
Brief: Grifols Gets FDA Approval To Start Phase 2 Trial With Immunoglobulin Eye Drops
Grifols rises after Q1 beat
Spanish stocks - Factors to watch on May 13
Brief: Grifols Confirms 2025 Guidance
Brief: Grifols Says German Regulator Approved Offer Document Submitted By Its Subsidiary Biotest
Australia's CSL evaluates China tariff exemptions for its US-made drugs
Brookfield may have to dig deeper to bag Grifols
Brief: Brookfield Says Is Not In Discussions With Grifols, Maintains Dialogue With Shareholders
Brief: Grifols' Board Has No Knowledge Of Resumed Takeover Talks With Brookfield
European stocks drop ahead of Trump's tariff announcement (updated)
Grifols shares jump after report on takeover talks resuming (updated)
Grifols jumps after report of Brookfield resuming takeover talks
Brookfield resumes Grifols takeover talks, El Confidencial reports
Spanish stocks - Factors to watch on April 2
Brief: Grifols Approves Its Unit's Delisting Purchase Offer For Biotest
Brief: Grifols Addresses Information Published In Media Article On March 8
Media: Grifols CFO Sees a Return to Public Debt Market for Refinancing- Bloomberg News
Grifols expects to boost revenue and free cash flow, shares soar